Author Archives: thedangerpoint

Globe Life … ‘Vaporized’

April 11, 2024 By in $SPSIBI, Biotech, Dr. John Campbell, Ed Dowd, GL, LABD, Life Insurance, SPBIO, XBI

Is This, The ‘Go-Forward’ Model?

In just one day, Globe Life closes down – 53.14%, on historic volume, over 35-million shares.

No matter the narrative, it shows just how fast a market can implode.

Years ago, while watching an episode of Wall Street Week, with Louis Rukeyser, one of his guests commented on a corporation that released (unexpectedly) bad earnings.

He said … ‘I believe in the cockroach theory. Where there’s one, there’s more’.

Does anyone think Globe Life is, or will be, an isolated incident? This could even be a ‘Lehman Moment‘ and we just don’t know it (not advice, not a recommendation).

Up-coming (potential) problems with life insurance have already been covered; best described in this brief four-minute clip, link here.

The Biotech Connection

The connection between biotech and life insurance can be correlated with this link and this one.

Biotech, XBI, Daily

The chart below, is slightly different from one’s typically presented on this site.

It’s on the daily timeframe but it’s compressed to better show the sector sub-dividing lower.

Yesterday’s Fibonacci analysis may still apply but we won’t really know until we see tomorrow’s action.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Globe Life Crash … -45%, So Far …

April 11, 2024 By in Biotech, GL, MET, The Speck

‘Fraud’ Is The Narrative

Here’s the latest news (as of 2:03 p.m., EST), link here.

Note, the article says the shares ‘tumbled’ … hardly, it’s a crash … take a look at the chart, link here.

The life insurance sector, and more specifically Globe Life (GL) along with Met Life (MET), have been on the watch list for reasons discussed many times on this site.

The Biotech Link

Possibly related (correlated) to the life insurance industry is biotech.

We’ll discuss that sector, XBI, in an upcoming update. The synopsis is that XBI could make a brief new daily high today (or at the open tomorrow).

If so, it could put the sector in a minor up-thrust position, while still in an overall down trend.

More later.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech … Beat Up & Down

April 10, 2024 By in $SPSIBI, Biotech, Federal Reserve, Interest Rates, LABD, SPBIO, XBI, ZeroHedge

Fibonacci Day 13

Biotech’s been beat up and down so much, you can lose track of what’s really happening.

Include the financial media side-show, and it’s a recipe for confusion and delay.

In the case of biotech XBI, it had a ‘change of character’ on March 21st, then morphed into a trading channel.

Now, it looks like it has a Fibonacci time correlation.

It all sounds complicated, so let’s take a look.

Biotech XBI, Daily

The original change of character, identified in this post.

Yesterday, Tuesday, was Fibonacci Day 13, from the point where the ‘change’ was noted.

It appears, the market used Tuesday, to post the right side (supply side) of the current trading channel.

Of course, there have been no ‘confirming’ hits on that right side so far; we just have one data point.

As the action unfolds, the key is to look for the market to adhere to the channel or tell us that something else is happening (not advice, not a recommendation).

Sorry, No Rate Cuts

That’s news to some.

On this site, it’s been a working premise for over a year.

Remember, back then, it was called ‘The Pivot’:

“Like ‘bread and circuses’, the ‘pivot’ discussion is a distraction … keeping the proletariat placated.”

Now, the man behind the curtain has been exposed, here and here, it may get very dangerous … as if it’s not already.

This post is being released (12:52 p.m., EST) before the Fed minutes. No telling what kind of volatility may, or may not, ensue from there.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Nat-Gas … The ‘Sleeper’

April 6, 2024 By in Gold & Silver, Natural Gas, UNG, Wyckoff

Any Bulls Left?

It’s all bearish on the Nat-gas front.

Way back in 2001, it was all bearish on the gold front as well; lows were around $254/oz. – $255/oz.

How did that work out?

No, Nat-gas is not gold but at this point, it’s possibly just as ignored as gold was, then.

The strategy or potential reasons for a rally in Nat-gas, have already been addressed here and here.

So, we’ll cut to the chase, looking at the proxy, UNG.

Natural Gas, UNG, Daily

It’s possible, the March 27th, penetration of support (covered here) and subsequent recovery, is a Wyckoff spring set-up (not advice, not a recommendation).

If we’re in a spring with the wedge in-effect, meaning, the market’s not going to morph into another structure, then it’s likely, Friday’s action was a test of both the spring and the wedge (breakout).

Supporting the ‘test’ scenario, we have Friday’s action pulling back to the lows; volume contracts by over 37%, when compared to the day prior, Thursday.

Of course, this is all very nuanced action and can be blown away at the next session.

However, as with our gold example, no one was looking for a major, long-term reversal at the time.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Bad News For Biotech

April 5, 2024 By in $SPSIBI, Federal Reserve, Interest Rates, LABD, SPBIO, XBI 1 Comment

Good News, If You’re Short

Yesterday, biotech (XBI) had the chance to reverse off Wednesday’s lows, continue higher into an upside move, a Wyckoff spring.

It didn’t happen.

The move failed spectacularly.

The ‘Street’ pays attention to such failed moves. Thus far, unless there’s some kind of massive demand, biotech XBI, has penetrated and tested support, now resistance, and is moving lower.

Strategy First

Recall, the work was done (three weeks ago) indicating high probability of a long-term reversal in this sector.

Adding some entertainment with the Fed is, or the Fed isn’t (going to cut rates). How about the Fed never was. 🙂

Until proven otherwise, we’re in a high, and higher, interest rate environment.

Biotech XBI, 4-Hour

Moving closer-in on the chart, the 4-Hour.

As we can see, on March 21st, XBI had a change of character.

Price action was relatively ordered and well behaved but then became more volatile on the 21st; it all fell apart, declining sharply on April 2nd.

At the point where the ‘change’ is noted, it also looks like XBI, began to form its (current) trading channel.

P&F Projection

If XBI, continues its decline, where’s it going?

What’s a likely target?

There are several methods that can be used; Fibonacci projection, measured move, and P&F to name a few.

A basic P&F projection is shown below:

What’s shown is the maximum projection range (not advice, not a recommendation).

As this post is being created (11:52 a.m., EST), XBI continues to grind its way higher in what’s likely a move to test resistance in the 90.50 – 90.60, area.

For the breakdown to be negated, we would need to see a decisive upside penetration of the right-side channel line.

It’s close but so far, price action is within ‘normal’ correction boundaries.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Silver Top?

April 4, 2024 By in David Weis, Ed Seykota, Gold & Silver, Silver Collapse, SLV, Wyckoff, zsl 4 Comments

Know Your Market

There’s been something wrong with the precious metal’s, gold and silver, for years.

Gold and silver used to move essentially in tandem, over the long term; not anymore.

This link shows there’s a huge divergence in the correlation between the two metals. Gold has launched higher, while silver has lagged.

Right around June of 2020, the correlation began to break down. What else was going on (or being ‘rolled out’) around June of 2020?

Recall, silver’s primarily an industrial metal; affected much more (than gold) by manufacturing demand.

Strategy First

Shown by the market itself, direct correlation between silver and gold no longer applies (or has somehow changed into a new construct), silver’s not confirming the ‘inflation’ shtick, possibly influenced more by industrial demand.

Thus, we have the following.

Silver SLV, Weekly

Just listening to what the market’s telling us, it says, when SLV, reaches a top and inflection point (to reverse lower), it tends to print heavy upside volume bar(s).

Looking at the chart, price action’s all over the place. Wide bars, volume spikes, the gamut.

Markets like this are unstable and usually can’t mount a sustained move in either direction.

Typically, if there’s going to be a breakout (or breakdown), price action tends to get tight, or get itself into a ‘coil’.

Even so, we need to account for the market itself.

Having traded silver futures contracts during the last run up and meltdown from 2011 – 2014, the silver market is thin and likes to ‘spike’.

That (spike) behavior is confirmed by Ed Seykota in Market Wizards and David Wies in his (formerly) daily market updates.

We may be at the beginning of a set-up for a Wyckoff up-thrust (above resistance) and then reversal.

A possible measured move for SLV (to be covered in another update), puts the tracking ETF, right around 25.60, about 2-pts. from where we are now (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech Breakdown

April 2, 2024 By in $SPSIBI, Biotech, LABD, SPBIO, Wyckoff, XBI

Surprising Weakness

When a market’s not performing as expected, then obviously, something else is going on.

The last update on biotech XBI, was expecting a bounce higher to take out potential stops in the area noted.

It’s not happening,

Instead, shown below, each bounce has less energy and, in the pre-market, XBI is trading lower.

Strategy First

Recall, we’re in a potential long-term reversal (Wyckoff up-thrust); based on the action of the market itself, that analysis is proving to be correct.

Biotech XBI, Daily

After each bounce, price action goes on to post new lows.

For yesterday’s action (Monday), not only do we have a new daily low but a new weekly low as well.

At this point in the pre-market (9:10 a.m., EST) XBI, is trading lower at 92.50, or – 1.44%.

We’re right at support levels and pressuring those levels.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

The Thrust Is Gone … Nat-Gas

April 1, 2024 By in BOIL, Natural Gas, UNG 1 Comment

Before It Can Go Higher …

Before Nat-Gas can reverse and head higher, it has to first, stop going lower.

One of the ways a market tells us it’s ready for reversal, is to print what’s called ‘shortening of the thrust’.

Essentially, each net movement over time (whether up or down), becomes shorter.

We can see that in Nat-Gas proxy, UNG, below.

Natural Gas UNG, ETF, Daily

Nat-Gas began its current decline around early October last year. Note, how each successive thrust lower has become shorter in net distance.

The inference is, ‘a reversal may be at hand’ (not advice, not a recommendation).

Recall, the prior post on UNG, link here, indicated the potential for reversal:

“The chart shows UNG, has penetrated support and is just ‘hanging’ there, unsure of what to do next.

It’s at The Danger Point®, where the potential risk of going long is least (not advice, not a recommendation).”

To be precise, in the futures market early the next day, a new low was posted; that new low was reversed by the open, with UNG higher.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Corn & The ‘Potato’

March 30, 2024 By in Corn, Derecho, Food Supply, Genesis 41, ice-age-farmer, Oil, Wyckoff

… A Plan (nearly) Comes Together

It’s been over a year since this post, forecasting the potential direction for corn.

Since then, as we’ll see below, the corn commodity tracking fund CORN, bottomed at 18.72, before reversing.

It came within 0.72-pts., of the forecasted (measured) move.

What we’re being told (by the market) at this point, is the analysis has been correct, thus far.

So, the obvious question is, ‘What’s next?’

Strategy First

For a potential answer and set-up, let’s not forget what launched CORN, in the first place, the Derecho, way back in August of 2020.

Noting the chart in the link above, we have a change of character; massive volume in the weeks leading up to the weather ‘event’.

Someone’s opening a huge position ahead of time.

Now, four years later, CORN hits its forecasted (retrace) target and is reversing. Is it time to go long?

Under ‘normal’ market conditions, that answer would probably be yes. (not advice, not a recommendation).

However, we should all know by now, we’re not in normal conditions and probably won’t be for years, if not decades.

No, we’re still waiting for the ‘Potato Head Gambit‘.

“What we’re looking for here, is some kind of Jimmy Carter type stunt where corn exports are halted in the name of ‘national security’ or some such thing.”

Corn Tracking Fund CORN, Weekly

Two Fibonacci projections are overlaid on the chart.

First, a simple retrace starting near ‘Derecho’ lows, to highs set during the week of April 29th, 2022.

Second, a counter-trend projection from those highs to the intermediate lows set during week of May 19th, 2023 and highs of June 23rd, week, the same year.

CORN has retraced 61.8%, which is also the 1:1 counter-trend projection. In addition, it’s the measured move from the wedge break.

The market has effectively confirmed the support area.

Oil Goes Negative … And Corn?

Remember that ‘anything can happen’. Oil futures made history by going negative.

We’re in a new construct, a new paradigm, our strategy should match accordingly.

Everyone has their own perspective and plan for the markets; fair enough.

From here, CORN could continue to new, all-time highs.

However, for my accounts, I’ll wait until such time it appears the downside risk is removed as much as possible.

One potential area for that ‘removal’ is the 76.4%, retrace in the vicinity of CORN @ 16 (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech, The Next Set-Up

March 28, 2024 By in $SPSIBI, Biotech, LABD, Martha Stokes, SPBIO, Spring-to-Up-Thrust, XBI 1 Comment

Breaks Channel … Heads For Potential Up-Thrust

The market is always right.

If it’s not behaving as expected, then it’s obviously doing something else.

In the case of biotech XBI, that something else, may be working its way to the next set-up.

Strategy First

Until price action proves otherwise, the overall long term reversal assessment of the sector has not changed (not advice, not a recommendation).

We’ve had a potential long-term up-thrust (reversal) that’s been covered here, and here.

That second link contains a 3-Day chart analysis.

Looking at the current price action and having it dictate what chart to use, we’ll switch to a 2-Day, which shows the potential more clearly.

Biotech XBI, 2-Day

The sector has failed to break below support in the 92 – 93, area. Instead, it has decided to bounce in what looks to be a possible minor spring-to-up-thrust.

We can see there’ve been two ‘hits’ on the upper resistance line. One, immediately after the up-thrust breakdown and one later … 4-bars later.

These hits essentially confirm the area, in effect, setting it up for potential penetration.

One has to think about where the stops are located.

If I was short this sector (I have been, but not currently), where would I place my stop?

Naturally, I’d put it right above the resistance (blue) line, exactly where everyone else has put theirs 🙂

Years ago, Martha Stokes wrote an update on why everybody gets stopped out of their trades, paraphrasing from this link:

‘The Market Makers don’t know you are there; they’re not interested in your tiny little stop order.

If your order does get taken out, it’s because too many small traders put their stops at the same location.

There’s an order imbalance. The market’s response is essentially automatic … take out the stops.’

With that, let’s see what happens next.

There’s no guarantee XBI, will penetrate the resistance area but if it does, we won’t be surprised.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279